Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Eribulin Mesylate|DRUG: Capecitabine
Sponsor: Consorzio Oncotech